Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune...
responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 3:35pm
RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion
Neither BioNTech or Pfizer will allow their mRNA vaccine knowledge & manufacturing capacity languish into oblivion. Instead both companies will be transitioning into therapeutic technologies like
...more
(83)
•••
CaseyL
X
View Profile
View Bullboard History
Comment by
CaseyL
on Apr 12, 2024 3:29pm
RE:RE:RE:CD8+ TiLs and T-cell exhaustion
"Drug Platform" Love it Noteable. ONCY has a great SALE aspects if results trun out. Just so happenes those results are turning out.... : )
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 1:45pm
RE:RE:RE:CD8+ TiLs and T-cell exhaustion
March 10, 2024 - " Pfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 1:40pm
RE:RE:CD8+ TiLs and T-cell exhaustion
With respect to ONCY partnerships it is important to know that while BioNTech is involved with Genentech (Roche) in the development of mRNA vaccine in the treatment of resected pancreatic cancer in
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 1:21pm
RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway
Background on OV + ICI posted in October 2023 which illustrates the reinvigorated interest in cancer "vaccines" as the future of cancer therapies. https://www.cancer.gov/news-events/cancer
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 1:10pm
RE:RE:RE:CAR-T update
April 12, 2024 - Roche subsidiary Genentech has terminated a cell therapy partnership with Adaptimmune Therapeutics worth up to $3 billion biobucks. The collaboration, inked in 2021
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 11:48am
RE:RE:Quentin30 is a pathological prevaricator.
Below is just one Quentin30 posts that shows he doesn't know what he is talking about ... particular about how the product is validated for long term stability and the amount of product involved
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 11:21am
RE:RE:Quentin30 is a pathological prevaricator.
If Quentin30 now claims to have worked in the biotech industry ( and now is trying to give the impression that he works for a brokerage company), then his experience is considerably narrow and limited
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 11:03am
RE:Quentin30 is a pathological prevaricator.
This thread was created in June 2023 because Quentin30 had repeatedly thrown "shade" over the stock that he said he owned - and he did so by "creating" misinformation, which was
...more
(1191)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Apr 12, 2024 10:56am
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timings
You alluded to being in the biotech industry yesterday, which I find inconceivable given your complete lack of understanding on anything to do with Biotech. How is that you don't understand
...more
(5041)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 12, 2024 10:54am
RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway
April 12, 2024 - " ..... a few key themes became apparent at the American Association for Cancer Research’s annual meeting [AACR24]. First and foremost, the programs presented are
...more
(1191)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Apr 12, 2024 10:47am
RE:RE:RE:RE:My my!…The entire basher team is working overtime tonight!
Oh I've checked, I can't wait to share my findings with the class. It's hilarious!! What are your current positions Mr Burry? You've continued to tell us all retrospectively
...more
(850)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Apr 12, 2024 10:23am
Lots of useless chatter overtop of my post/worth a repost
It has been a long time of silence, with anything related to upcoming phase 3. That being either the pancreatic or MBc Cancers. In the background the science, AKA on- going trial(s) & various
...more
(67)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Apr 12, 2024 10:09am
RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timings
And that is your only response.. Isn't it time for you to post some details of some spurious trial with the vaguest of connections to ONCY.. I hear the local laundromat was bought by another
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test